Oct 2 (Reuters) - AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test ...

Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and ...

Revolution Medicines' daraxonrasib is the first drug that can broadly tackle one of the main drivers of pancreatic cancer.

Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR ...

People with chronic heartburn are asked to join a study to identify their risk of developing cancer.

The approach is still experimental, but a newly approved drug, advances in early detection, and promising research involving ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Foghorn Therapeutics is reducing its workforce by roughly 40% after Eli Lilly ended a cancer drug development partnership, forcing the Massachusetts-based biotech to redirect reso ...

When an ad for a new cancer drug pops up in your newsfeed, it might look like an overnight success. But even developing a ...

The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial ...

Oct 1 (Reuters) - Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage ...